Press Releases

  • December 08, 2021
  • RSNA and RadSite Team Up to Promote Pilot Program for FDG PET/CT Biomarker Profile
  • The Radiological Society of North America (RSNA) is teaming up with RadSite™, a leading accreditation organization for advanced diagnostic imaging, to pilot the RSNA Quantitative Imaging Biomarkers Alliance (QIBA) Profile for fluorodeoxyglucose (FDG) PET/CT imaging. This Profile provides both qualitative and quantitative data for single-time-point and multi-time-point comparative assessments covering the full spectrum of oncology therapy, including diagnosis, prognosis, staging and treatment efficacy.

  • October 14, 2021
  • RadSite Announces First Wave of Cone Beam CT Imaging Accreditations
  • RadSite™, a leading accreditation organization promoting quality-based imaging practices, announced today that it has completed its first wave of accrediting Cone Beam CT imaging suppliers in the specialty areas of Dental, Maxillofacial, Orthopedics, and Podiatry. RadSite’s Dental and Medical Cone Beam CT Accreditation Programs were launched earlier this year after receiving recognition by the U.S. Centers for Medicare and Medicaid Services.

  • September 22, 2021
  • RadSite Announces Complimentary Fall Webinar Series
  • RadSite™, a leading accreditation organization promoting quality-based imaging practices, announced today its fall webinar series on updates to key accreditation standards. Starting on October 26, the monthly webinars address recent imaging trends covering RadSite Standards, reimbursement strategies, and leadership opportunities.

  • May 28, 2021
  • Center for Genomic Interpretation Launches ELEVATEGENETICS BRILLIANT Program
  • The Center for Genomic Interpretation (CGI) recently launched the ELEVATEGENETICS BRILLIANT™ Program. The innovative technical competency assessment is a game changer in evaluating the accuracy of genetic and genomic lab findings. The new program fills existing regulatory and accreditation gaps by assessing how well laboratory DNA sequencing tests can detect and rigorously classify important mutations and therapeutic biomarkers, especially in genetic sequences that are technically challenging. The dynamic CGI solution supports a wide range of stakeholders by helping ensure more accurate genetic/genomic testing and reporting, which improves the fidelity of patient treatment plans and promotes better clinical outcomes.

Scroll to Top